Targeting RAGE in sepsis.
The receptor of advanced glycation endproducts (RAGE) is a multiligand receptor that upon activation causes sustained activation of multiple inflammatory pathways. Recent evidence, summarized in a review by Bopp and colleagues in this issue of Critical Care, has implicated RAGE as a potential therapeutic target in sepsis. Here, we discuss several open issues that need to be addressed before anti-RAGE strategies can enter the sepsis clinical trial arena.
van Zoelen
Marieke A D
MA
van der Poll
Tom
T
D000818:Animals; D006801:Humans; D051379:Mice; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors* / Q000502:physiology; D018805:Sepsis / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology
D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic